#USA #New York #Securities Fraud #Lawsuit #Ultragenyx

Levi & Korsinsky Announces Class Action Against Ultragenyx Pharmaceutical Inc.

In a recent development, Levi & Korsinsky, LLP has informed investors in Ultragenyx Pharmaceutical Inc. (tickers: NASDAQ: RARE) about a class action lawsuit concerning alleged securities fraud. This lawsuit represents an essential juncture for shareholders who may have suffered losses between August 3, 2023, and December 26, 2025. If you have been affected by these events, it's critical to understand the implications and your potential rights going forward.

Definition of the Class

The lawsuit is aimed at recovering losses incurred by investors who were adversely impacted by the alleged fraudulent activities carried out by the company. The class is defined as those shareholders who acquired shares during the specified timeframe and faced financial losses as a result of misleading information disseminated by Ultragenyx.

Accusations and Case Details

The complaint outlines that Ultragenyx's management provided overly optimistic statements to the shareholders while failing to disclose the true risks associated with the clinical trials related to their drug, setrusumab. The defendants are accused of intentionally concealing material facts, particularly concerning the drug's purported efficacy in reducing clinical fracture rates.

Despite initial claims that setrusumab could significantly increase bone density, the lawsuit alleges that this outcome did not correlate with a reduced incidence of fractures. This discrepancy came to light when, on December 29, 2025, Ultragenyx reported that the Phase III clinical trials, known as the Orbit and Cosmic studies, did not meet the primary endpoints necessary to confirm efficacy against the placebo.

When this information surfaced, the company witnessed a catastrophic drop in its stock price, plummeting by 42.32% in a single day—from a closing price of $34.19 per share on December 26, 2025, to $19.72 per share by December 29, 2025. This dramatic decline has significantly shaken investor confidence and raised concerns over the integrity of Ultragenyx's disclosures.

Next Steps for Investors

For those who experienced losses during this timeframe, it’s important to take note that the deadline to request to be named as the lead plaintiff in this case is April 6, 2026. It's crucial to acknowledge that participating in this potential recovery does not necessitate serving as a lead plaintiff.

No Financial Cost to Participate

If you are a class member impacted by the alleged fraud, you may stand to receive compensation without incurring any out-of-pocket expenses or fees. Levi & Korsinsky emphasizes that there is no obligation or cost associated with participating in this lawsuit, encouraging affected investors to come forward without fear of financial implications.

The Reputation of Levi & Korsinsky

Levi & Korsinsky possesses a robust track record in securing favorable outcomes for distressed investors across their 20 years of experience. With their comprehensive expertise in complex securities litigation and a dedicated team of over 70 professionals, they stand as one of the leading securities litigation firms in the United States, consistently highlighted in ISS Securities Class Action Services' Top 50 Report for the past seven years. Their reputation as advocates for shareholder rights positions them well to navigate this challenging legal landscape.

Contact Information

For further communication and inquiries, shareholders can reach out directly to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. at the firm's New York office:

• - Address: 33 Whitehall Street, 27th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

Investors are encouraged to remain vigilant and informed as this case progresses, ensuring their rights as shareholders are protected during these pivotal developments.